EMA - European Medicines Agency · March 30, 2023

EMA recommends revoking marketing authorisation for Tavneos

EMA recommends withdrawal of Tavneos marketing authorisation because benefits no longer outweigh risks.

Low obligation Product class Pharmaceuticals EU-wide Pharmaceuticals

Benefits no longer proven to outweigh risks of treatment

Read the official source ↗

Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.